Figure 2.
AD/ACLF plasma proresolving and inflammation-initiating mediator profiles. Plasma collected pre and post albumin administration and lipid mediators profiled using liquid chromatography–tandem mass spectrometry LM metabololipidomics. (A) Representative multiple reaction chromatograms for identified lipid mediators and (B) tandem mass spectrometry spectrum used in identification of AT-lipoxins A4 and MaR1. Representative of 10 patients. AA, arachidonic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; m/z, mass to charge ratio.